Vanessa Meier-Stephenson1, Shelly McNeil2, Andrea Kew3, Jennifer Sweetapple4, Kara Thompson5, Kathryn Slayter6. 1. MD, PhD, was, at the time of manuscript preparation, an Internal Medicine resident with the Faculty of Medicine, Dalhousie University, and the Department of Medicine, Capital Health, Halifax, Nova Scotia. She is currently completing an Infectious Diseases residency at the University of Calgary, Calgary, Alberta. 2. MD, is with the Faculty of Medicine, Dalhousie University, and the Department of Medicine and Division of Infectious Diseases, Capital Health, Halifax, Nova Scotia. 3. MD, is with the Faculty of Medicine, Dalhousie University, and the Department of Medicine and Division of Hematology, Capital Health, Halifax, Nova Scotia. 4. MSc, is with the Department of Pharmacy, Capital Health, Halifax, Nova Scotia. 5. MSc, is with the Research Methods Unit, IWK Health Centre and Capital Health, Halifax, Nova Scotia. 6. PharmD, is with the Department of Medicine, the Division of Infectious Diseases, and the Department of Pharmacy, Capital Health, Halifax, Nova Scotia.
Abstract
BACKGROUND: Overwhelming postsplenectomy infection is a serious potential outcome for patients who have undergone resection of the spleen and is associated with a high mortality rate. The most common bacterial causes are the encapsulated organisms Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae type B, all of which are vaccine-preventable. Current guidelines recommend vaccination against these 3 bacteria, but adherence to these guidelines is less than ideal. In 2007, a "perisplenectomy vaccination kit" was introduced at the authors' institution to improve compliance with immunization guidelines by making the vaccines and necessary information for patients and providers more readily available. OBJECTIVE: To evaluate and compare vaccination rates for patients who underwent splenectomy before and after introduction of the perisplenectomy vaccination kit and, secondarily, to identify any characteristics unique to those who did not receive appropriate perisplenectomy vaccinations. METHODS: In this observational study, performed at the QEII Health Sciences Centre of Capital Health in Halifax, Nova Scotia, data were reviewed for patients who underwent splenectomy between 2008 and 2011. Vaccination rates and other descriptive statistics were calculated and compared with data for a 3-year period before implementation of the program. RESULTS: Vaccination rates in the 3-year period following implementation of the perisplenectomy vaccination kit were 100% against S. pneumoniae, 97% against N. meningitidis, and 93% against H. influenzae type B. The corresponding rates in the 3 years before introduction of the kit were 91%, 75%, and 68%, respectively. No characteristics predicting inadequate immunization were identified in univariate or multivariate analysis. CONCLUSION: Introduction of a pharmacy-driven perisplenectomy vaccination kit program improved rates of appropriate vaccination for patients who underwent splenectomy.
BACKGROUND: Overwhelming postsplenectomy infection is a serious potential outcome for patients who have undergone resection of the spleen and is associated with a high mortality rate. The most common bacterial causes are the encapsulated organisms Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae type B, all of which are vaccine-preventable. Current guidelines recommend vaccination against these 3 bacteria, but adherence to these guidelines is less than ideal. In 2007, a "perisplenectomy vaccination kit" was introduced at the authors' institution to improve compliance with immunization guidelines by making the vaccines and necessary information for patients and providers more readily available. OBJECTIVE: To evaluate and compare vaccination rates for patients who underwent splenectomy before and after introduction of the perisplenectomy vaccination kit and, secondarily, to identify any characteristics unique to those who did not receive appropriate perisplenectomy vaccinations. METHODS: In this observational study, performed at the QEII Health Sciences Centre of Capital Health in Halifax, Nova Scotia, data were reviewed for patients who underwent splenectomy between 2008 and 2011. Vaccination rates and other descriptive statistics were calculated and compared with data for a 3-year period before implementation of the program. RESULTS: Vaccination rates in the 3-year period following implementation of the perisplenectomy vaccination kit were 100% against S. pneumoniae, 97% against N. meningitidis, and 93% against H. influenzae type B. The corresponding rates in the 3 years before introduction of the kit were 91%, 75%, and 68%, respectively. No characteristics predicting inadequate immunization were identified in univariate or multivariate analysis. CONCLUSION: Introduction of a pharmacy-driven perisplenectomy vaccination kit program improved rates of appropriate vaccination for patients who underwent splenectomy.
Authors: A J J Lammers; D Veninga; M J M H Lombarts; J B L Hoekstra; P Speelman Journal: Eur J Clin Microbiol Infect Dis Date: 2010-01-22 Impact factor: 3.267
Authors: J O'Donnell; G McGreal; P Daly; R Crowley; M C Barry; P Broe; D J Bouchier-Hayes Journal: Ir J Med Sci Date: 2004 Jul-Sep Impact factor: 1.568
Authors: Antonio Di Sabatino; Marco Vincenzo Lenti; Francesco Paolo Tinozzi; Marina Lanave; Ivana Aquino; Catherine Klersy; Piero Marone; Carlo Marena; Andrea Pietrabissa; Gino Roberto Corazza Journal: Intern Emerg Med Date: 2017-08-10 Impact factor: 3.397